Viatris (VIA) Stock Price & Analysis
VIA Stock Chart & Stats
- Day’s Range
- EUR 17.06 - EUR 17.18
- 52-Week Range
- EUR 8.68 - EUR 17.18
- Previous Close
- EUR 17.12
- Volume
- 1,789
- Average Volume (3M)
- 1,976
- Market Cap
- EUR 19.51B
- Enterprise Value
- EUR 30.69B
- Total Cash (Recent Filing)
- EUR 1.51B
- Total Debt (Recent Filing)
- EUR 13.63B
- Price to Earnings (P/E)
- ―
- Beta
- 0.62
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 0.57
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.40%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Robust operating and free cash flow provides Viatris with internal funding for debt repayment, shareholder returns, and portfolio investment. The combination of strong cash earnings and working-capital discipline supports financial flexibility even while reported earnings remain under pressure.
Raised Operating Outlook
Management’s higher 2026 guidance, following a quarterly revenue, EBITDA, and EPS beat, indicates confidence in execution and portfolio momentum. Continued adjusted profit growth would strengthen cash generation and support a more durable recovery in operating performance.
Accretive Portfolio Expansion
The proposed Pacira acquisition broadens Viatris beyond its traditional generic base with established, patent-protected non-opioid pain products. Viatris expects to use its intellectual property expertise and global infrastructure to extend product lifecycles, expand reach, and capture synergies.
Bears Say
Weak GAAP Profitability
Negative operating profit and net income weaken the quality and consistency of Viatris’s reported earnings despite solid adjusted EBITDA. Lower gross margins and historical earnings volatility may limit retained capital, reduce resilience, and make sustainable shareholder returns more difficult.
Elevated Leverage
Viatris has improved its leverage trajectory, but debt remains substantial relative to equity and creates an ongoing obligation against cash flow. This can constrain capital allocation and leave less flexibility for acquisitions, investment, or unexpected operating setbacks.
Competitive And Policy Pressure
Competition in established brands and high-margin products can produce price erosion and weaker product contributions over time. This pressure is compounded by changing China procurement policy, which may reduce hospital-channel volumes and make growth and margin improvement harder to sustain.
Viatris News
VIA FAQ
What was Viatris’s price range in the past 12 months?
What is Viatris’s market cap?
When is Viatris’s upcoming earnings report date?
How were Viatris’s earnings last quarter?
Is Viatris overvalued?
Does Viatris pay dividends?
What is Viatris’s EPS estimate?
How many shares outstanding does Viatris have?
What happened to Viatris’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Viatris?
What is the TipRanks Smart Score and how is it calculated?
Viatris Stock Smart Score
Company Description
Viatris
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith
- Employees
- 30,000
- Website
- www.viatris.com
- Address
- Robert J. Coury Global Center, Canonsburg, PA, 15317, US
Viatris (VIA) Earnings & Revenues
VIA Company Deck
VIA Earnings Call
Earnings Call SentimentPositive
The call conveyed predominantly positive operational and strategic momentum: the company beat expectations in Q2 on revenue, EBITDA and EPS, raised full-year guidance across key metrics, showed margin improvement, strong cash generation, aggressive capital returns, meaningful pipeline and regulatory progress (Gwyn Lo approval, Nefecon topline, Phase III programs on track). Offsetting this, notable near-term challenges include Nashik manufacturing disruptions (with a $100–$150 million H2 revenue headwind), emerging markets supply constraints, competitive pressure in some developed-market products, and China procurement policy uncertainty that may moderate future growth. Overall, management framed the challenges as mostly short-term and fully considered in the updated guidance while emphasizing long-term growth opportunities and financial flexibility.
View all DE:VIA earnings summariesVIA Net sales Breakdown
- 64.45% Brands
- 35.55% Generics
VIA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 2 | 6 |
| Technical Analysis | 2 | 2 | 6 |
| Moving Averages | 12 | 0 | 0 |